Ftse Mib
33.749,09
0,12%
DAX
18.323,86
0,89%
S&P 500
5.469,30
0,39%
NASDAQ
17.717,65
1,26%
Bitcoin
61.467,43
-0,56%
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ NeuroMetrix Inc (NURO) NeuroMetrix Inc (NURO) Notizie

NURO

NeuroMetrix (NURO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NURO
DataOraFonteTitoloSimboloCompagnia
31/05/202419:15Edgar (US Regulatory)Form SD - Specialized disclosure reportNASDAQ:NURONeuroMetrix Inc
24/05/202423:13Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NURONeuroMetrix Inc
15/05/202422:00GlobeNewswire Inc.NeuroMetrix Reports Q1 2024 Business HighlightsNASDAQ:NURONeuroMetrix Inc
15/05/202418:33Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:NURONeuroMetrix Inc
15/05/202417:19Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NURONeuroMetrix Inc
19/04/202414:00GlobeNewswire Inc.NeuroMetrix Announces Steps Taken to Enhance Shareholder ValueNASDAQ:NURONeuroMetrix Inc
14/03/202414:00GlobeNewswire Inc.NeuroMetrix Announces Publication of Study Demonstrating that DPNCheck Accurately Diagnoses Diabetic Peripheral NeuropathyNASDAQ:NURONeuroMetrix Inc
13/03/202414:00GlobeNewswire Inc.NeuroMetrix announces that over 2000 patients with fibromyalgia have been prescribed Quell® FibromyalgiaNASDAQ:NURONeuroMetrix Inc
04/03/202422:12Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:NURONeuroMetrix Inc
01/03/202423:07Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NURONeuroMetrix Inc
27/02/202422:45Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:NURONeuroMetrix Inc
27/02/202422:00Edgar (US Regulatory)Form SC 13D - General statement of acquisition of beneficial ownershipNASDAQ:NURONeuroMetrix Inc
22/02/202413:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NURONeuroMetrix Inc
22/02/202413:00GlobeNewswire Inc.NeuroMetrix Reports Q4 and Full Year 2023 Business HighlightsNASDAQ:NURONeuroMetrix Inc
20/02/202420:49Edgar (US Regulatory)Form SCHEDULE 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:NURONeuroMetrix Inc
15/02/202415:00GlobeNewswire Inc.NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2023 Business Highlights Conference CallNASDAQ:NURONeuroMetrix Inc
13/02/202415:00GlobeNewswire Inc.NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder ValueNASDAQ:NURONeuroMetrix Inc
12/12/202315:00GlobeNewswire Inc.NeuroMetrix Reports Encouraging Results from Pilot Clinical Trial of Quell® in Post-Acute COVID-19 Syndrome (Long COVID)NASDAQ:NURONeuroMetrix Inc
05/12/202315:00GlobeNewswire Inc.NeuroMetrix Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell® Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN)NASDAQ:NURONeuroMetrix Inc
20/11/202315:00GlobeNewswire Inc.NeuroMetrix Announces One-for-Eight Reverse Stock SplitNASDAQ:NURONeuroMetrix Inc
26/10/202313:00GlobeNewswire Inc.NeuroMetrix Reports Q3 2023 Business HighlightsNASDAQ:NURONeuroMetrix Inc
23/10/202317:13GlobeNewswire Inc.NeuroMetrix, Inc. Announces Date for Third Quarter 2023 Business and Financial Highlights Conference CallNASDAQ:NURONeuroMetrix Inc
02/10/202315:00GlobeNewswire Inc.NeuroMetrix and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with FibromyalgiaNASDAQ:NURONeuroMetrix Inc
11/09/202313:59Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:NURONeuroMetrix Inc
27/07/202313:00GlobeNewswire Inc.NeuroMetrix Reports Q2 2023 Business HighlightsNASDAQ:NURONeuroMetrix Inc
20/07/202319:00GlobeNewswire Inc.NeuroMetrix, Inc. Announces Date for Second Quarter 2023 Business and Financial Highlights Conference CallNASDAQ:NURONeuroMetrix Inc
11/07/202315:00GlobeNewswire Inc.NeuroMetrix Announces Sales Force Expansion for Quell FibromyalgiaNASDAQ:NURONeuroMetrix Inc
28/06/202315:00GlobeNewswire Inc.Recent Publications Demonstrate Utility of DPNCheck® for Identifying High-Risk Diabetes PatientsNASDAQ:NURONeuroMetrix Inc
07/06/202315:00GlobeNewswire Inc.Diabetic Peripheral Neuropathy Screening That Includes DPNCheck® Predicts Mortality In A Prospective Clinical StudyNASDAQ:NURONeuroMetrix Inc
31/05/202323:22Edgar (US Regulatory)Specialized Disclosure Report (sd)NASDAQ:NURONeuroMetrix Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:NURO

La tua Cronologia

BIT
UCG
Unicredit
BIT
SPM
Saipem
BIT
STLAM
Stellantis NV
BIT
ISP
Intesa Sanpaolo
BIT
STMMI
ST Microelectronics
BIT
ENI
Eni
BIT
ENEL
Enel
BIT
FCTAAW
Fincantieri
BIT
FCT
Fincantieri
BIT
TIT
Telecom Italia
BIT
RACE
Ferrari NV
BIT
BPE
Bper Banca
BIT
LDO
Leonardo
BIT
BMPS
Banca Monte Dei Paschi D...
BIT
TEN
Tenaris
BIT
PRY
Prysmian
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network